Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase

BACKGROUND: Despite overexpression of the ErbB (EGFR/HER2/ErbB3/ErbB4) family in castration-resistant prostate cancer (CRPC), some inhibitors of this family, including the dual EGFR/HER2 inhibitor lapatinib, failed in Phase II clinical trials. Hence, we investigated mechanisms of lapatinib resistanc...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Cancer
Autors principals: Jathal, Maitreyee K., Steele, Thomas M., Siddiqui, Salma, Mooso, Benjamin A., D’Abronzo, Leandro S., Drake, Christiana M., Whang, Young E., Ghosh, Paramita M.
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6738116/
https://ncbi.nlm.nih.gov/pubmed/31209328
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-019-0496-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars